Ahmed Hamdy

ALZA Corp. provides drug delivery solutions and develops pharmaceutical products. The company applies its delivery technologies to develop pharmaceutical products with enhanced therapeutic value for its own portfolio and for many of the world's leading pharmaceutical companies. The company was founded by Martin Gerstel and Alejandro Zaffaroni in 1968 and is headquartered in Vacaville, CA.

Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ.

Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA.

Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands.

Andes Biotechnologies SA researches and develops effective treatments against cancer. It has developed a new proprietary technology based on the discovery of a novel family of RNA targets of mitochondrial origin that when disrupted by anti-sense technology they selectively destroy cancer cells. The company was founded by Luis O. Burzio, Arturo Yudelevich and Pablo D.T. Valenzuela in 2008 and is headquartered in Santiago, Chile.